NIKKEI 225
38,196.36 -77.69 (-0.20%) HANG SENG
17,944.30 +181.27 (+1.02%) CRUDE OIL
79.35 +0.35 (+0.44%) GOLD FUTURES
2,334.20 +23.20 (+1.00%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,758.78 -1,894.63 (-3.98%)
Sanofi SA (SNW.SG)
| Previous close | 91.47 |
| Open | 91.51 |
| Bid | 92.50 x 50000 |
| Ask | 92.62 x 125000 |
| Day's range | 91.46 - 93.16 |
| 52-week range | 81.08 - 104.18 |
| Volume | |
| Avg. volume | 989 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance
Why Wall Street no longer fears sprawling impact from the weight loss drug craze
Obesity drugs, known as GLP-1s, continue to be all the rage in 2024. But doomsday predictions of long-term impact to other industries may be cooling.
- Yahoo Finance
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
Several big pharma companies are rushing into the GLP-1 obesity space, which currently has two market leaders. How they plan to take some of that market share will be the story of the drug class for 2024.
- Reuters
UPDATE 2-US CDC says there's urgent need to increase respiratory vaccine coverage
The U.S. Centers for Disease Control and Prevention (CDC) on Thursday issued an alert urging healthcare providers to increase immunization coverage for influenza, COVID-19 and respiratory syncytial virus (RSV). The health regulator said that low vaccination rates, coupled with ongoing increases in respiratory disease activity, could lead to more severe disease and increased healthcare capacity strain in the coming weeks. Healthcare providers should recommend antiviral medications for influenza and COVID-19 for all eligible patients, especially older adults and people with certain underlying medical condition, the CDC said.
